The role of metabolic syndrome in the development of polycystic ovary syndrome in adolescence

被引:0
|
作者
Avramenko, N. V. [1 ,2 ]
Kabachenko, O. V. [2 ]
Barkovskyi, D. Ye. [2 ]
Sierykh, K. V. [2 ]
机构
[1] Zaporizhzhia State Med & Pharmaceut Univ, Fac Postgrad Educ, Zaporizhia, Ukraine
[2] Zaporizhzhia State Med & Pharmaceut Univ, Fac Postgrad Educ, Dept Obstet Gynecol & Reprod Med, Zaporizhia, Ukraine
关键词
obesity; metabolic syndrome; polycystic ovary syndrome; adolescence; diagnosis; treatment; prevention; ASSOCIATIONS; MANAGEMENT; OBESITY; HEALTH; RISK;
D O I
10.14739/2310-1210.2023.3.251479
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The review article presents an analysis of the metabolic syndrome problem in children and adolescents, its role in the development of polycystic ovary syndrome (PCOS) in accordance with the latest International guidelines and modern literature. The urgency of the problem lies in the rapid spread of overweight among children in the world and, consequently, the growth of alimentary -de-pendent pathology. One of the major consequences of weight problems is metabolic syndrome (MS). There are still no clear MS criteria for children and adolescents. IDF suggests using IDF criteria for adults. Priority in the pathogenesis of MS is given to insulin resistance (IR), which is associated with puberty. The problem of IR assessment remains. HOMA-IR and QUICKI methods are not considered reliable tests to determine IR, so the assessment is based on clinical signs (hyperglycemia, dyslipidemia, abdominal obesity, hypertension). Obesity and IR can be predictors of PCOS, which can often be associated with puberty. Pathological signs of the syndrome ty-pical for adults in adolescence may be a manifestation of the physiological course of puberty. Obligative criteria for the diagnosis of PCOS in adolescence are irregular menstruation/oligomenorrhea, proven biochemically and clinically hyperandrogenemia). First-line therapy for PCOS in adolescents with MS is weight loss and dosed exercise, which helps to normalize a hormonal balance. Drug treatment may include insulin-sensitizing drugs (metformin), antiandrogens (spironlactone, flutamide, cyproterone acetate), 5-alpha-reductase inhibitors (finasteride), combined oral contraceptives, inositol. Prevention of overweight, obesity in children can prevent the development of IR and, accordingly, associated MS and PCOS, reproductive health disorders. Prevention measures are aimed at avoiding maternal obesity, gestational diabetes, malnutrition and smoking during pregnancy, promoting breastfeeding and physical activity.
引用
收藏
页码:255 / 261
页数:7
相关论文
共 50 条
  • [1] Polycystic ovary syndrome in adolescence
    Buggs, C
    Rosenfield, RL
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2005, 34 (03) : 677 - +
  • [2] Polycystic ovary syndrome in adolescence
    Bruni, Vincenzina
    Dei, Metella
    Nannini, Sara
    Balzi, Daniela
    Nuvolone, Daniela
    WOMEN'S HEALTH AND DISEASE, 2010, 1205 : 175 - 184
  • [3] Polycystic ovary syndrome in adolescence
    Blank, Susan K.
    Helm, Kristin D.
    McCartney, Christopher R.
    Marshall, John C.
    MENSTRUAL CYCLE AND ADOLESCENT HEALTH, 2008, 1135 : 76 - 84
  • [4] Polycystic ovary syndrome in adolescence
    Driscoll, DA
    SEMINARS IN REPRODUCTIVE MEDICINE, 2003, 21 (03) : 301 - 307
  • [5] Polycystic ovary syndrome in adolescence
    Driscoll, DA
    WOMEN'S HEALTH AND DISEASE: GYNECOLOGIC AND REPRODUCTIVE ISSUES, 2003, 997 : 49 - 55
  • [6] Polycystic Ovary Syndrome in Adolescence
    Joham, Anju E.
    Pena, Alexia S.
    SEMINARS IN REPRODUCTIVE MEDICINE, 2022, 40 (01/02) : E1 - E8
  • [7] Polycystic ovary syndrome in adolescence
    Baumann, EE
    Rosenfield, RL
    ENDOCRINOLOGIST, 2002, 12 (04): : 333 - 348
  • [8] Metabolic role of hepassocin in polycystic ovary syndrome
    Coskun, E. inci
    Omma, T.
    Taskaldiran, I.
    Firat, S. N.
    Culha, C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (11) : 5175 - 5183
  • [9] Risk factors in adolescence for the development of polycystic ovary syndrome
    Morin-Papunen, Laure
    GYNAKOLOGE, 2016, 49 (11): : 838 - 845
  • [10] Polycystic ovary syndrome and metabolic syndrome
    Auernhammer, CJ
    Engelhardt, D
    Parhofer, KG
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (18) : 971 - 977